In compliance with current regulations, let us know which audience you belong to:
A recent scientific paper, published on Cornea, the Journal of Cornea and External Disease, by Sharon D’Souza (MD), Rohit Shetty (MD, PhD) et al., has confirmed that our Light Modulation® LLLT technology, employed jointly with our Optimal Power Energy® IPL technology, is the key factor in effectively managing the most severe cases of recalcitrant MGD.
The purpose of the study was that of evaluating the effects of combined light therapy [intense pulsed light (IPL) and low-level light therapy (LLLT)] on clinical and molecular outcomes in evaporative DED with meibomian gland dysfunction (MGD).
Directly citing the conclusions of the paper:
Combined light therapy shows promising results in patients with chronic MGD and DED, even in recalcitrant cases. Clinical and molecular factor alterations support the improved symptomatology and reduced inflammation.
D'Souza, S., Iyappan, G., Dickman, M. M., Thakur, P., Mullick, R., Kundu, G., ... & Shetty, R. (2021). Clinical and Molecular Outcomes After Combined Intense Pulsed Light Therapy With Low-Level Light Therapy in Recalcitrant Evaporative Dry Eye Disease With Meibomian Gland Dysfunction. Cornea.